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Abstract
Cytokines perform ever-increasing roles in both, the regulation of general homeostasis and in orchestrating the immune response during
disease. To ensure that control of the cytokine network is tightly regulated, nature has developed a series of systems designed for this
purpose. In this respect, researchers have placed considerable emphasis on identifying and characterising the regulatory properties of soluble
cytokine receptors. These proteins bind their ligands with similar affinities to those of their cognate transmembrane receptors and are
effective at prolonging the circulating half-life of cytokines they bind. However, it is the individual capacity of these soluble receptors to act
as either antagonists or agonists which has been the principal focus of most research studies. This review provides an overview of the
activities of soluble cytokine receptors, but primarily concentrates on those that possess agonistic properties.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Mechanisms of soluble receptor production
A number of soluble proteins corresponding to the
extracellular portions of transmembrane receptors and adhe-
sion molecules have now been identified in biological
fluids. These factors appear to retain their binding character-
istics and typically function to act as natural antagonists,
carrier molecules or chaperones to protect their ligands from
proteolytic degradation and in some cases act as biological
agonists. Consequently, the cellular release of these soluble
receptors is tightly regulated, and is typically controlled via
one of two mechanisms (Fig. 1) [1,2]. First, differential
mRNA splicing can lead to the secretion of soluble proteins
that lack cytoplasmic and membrane-spanning domains of
the cognate cell-associated protein. In many instances the
DNA rearrangement that ensues as part of the splicing
process results in the creation of reading frame shifts and
the generation of novel COOH-terminal sequences, which
may or may not have an impact on the biological properties
of these proteins (Fig. 1). Soluble receptors generated
through differential mRNA splicing include receptors for
interleukin-4 (IL-4), epidermal growth factor (EGF) and
leukemia inhibitory factor (LIF) (Table 1) [1]. The second
mechanism involves liberation of the soluble receptor
directly from the cell surface following proteolytic cleavage
of the membrane-anchored cognate protein (Fig. 1). The
proteases involved have been demonstrated to belong to the
ADAM family of metalloproteases. This newly recognised
group of cell membrane expressed metalloproteases is
characterized by the presence of a disintegrin domain
COOH-terminal to the Zn+ +-protease domain [3,4]. Regu-
latory proteins processed by limited proteolysis include
soluble receptors for IL-1, IL-2, TNFa, platelet-derived
growth factor and the adhesion molecule L-selectin
(CD62L) (Tables 1 and 2).
Although the generation of soluble mediators that serve
antagonistic properties is largely uncomplicated, production
of soluble receptors which facilitate agonistic functions
appears to be far more complex. This is clearly illustrated
by studies that have assessed the activities of the soluble IL-
6 receptor (sIL-6R) (see below). Although IL-6R expression
is largely confined to hepatocytes and sub-populations of
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leukocytes, IL-6 bioactivity can also be controlled by a
naturally occurring sIL-6R [5,6]. The sIL-6R is a principal
component in the regulation of IL-6 responses and forms an
[sIL-6R/IL-6] complex capable of directly activating cells
via membrane-bound glycoprotein 130 (gp130) [7]. Con-
sequently, the [sIL-6R/IL-6] complex is an agonist for cell
types that, although expressing gp130, are normally non-
responsive to IL-6 itself. Thus, when thinking about the
inflammatory potential of IL-6, it is essential to consider not
only the action of IL-6 itself, but also the effect sIL-6R may
have on cellular processes (see blow).
2. The IL-1 receptor system
IL-1 binds to two types of receptors on the cell mem-
brane, of which only type I (IL-1RI) transduces signals
together with the recently identified coreceptor IL-1 recep-
tor accessory protein (IL-1RAcP). The type II (IL-1RII)
functions as a decoy receptor without participating in IL-1
signaling. It has recently been proposed that upon IL-1
binding, the IL-1RII can recruit IL-1RAcP into a nonfunc-
tional trimeric complex and thus modulate IL-1 signaling
by sequestering the coreceptor molecule from the signaling
IL-1RI. In this mechanism of coreceptor competition, the
ratio between IL-1RII and IL-1RI is a central factor in
determining the cellular responsiveness to IL-1 [8]. Inter-
estingly, the extracellular domain of the type II IL-1
receptor is released from many cells (Fig. 1) by a metal-
loprotease [9] and can function as a specific inhibitor of IL-
1 activity. The soluble IL-1R retains its affinity for the
ligand IL-1. Upon shedding, the affinity of the soluble
receptor for the naturally occuring IL-1 receptor antagonist,
however, drops by a factor of 2000 when compared with
the cell surface receptor [10]. Therefore, the type II sIL-1R
inhibits IL-1 by competing for the interaction of mature IL-
1 with the type I IL-1 receptor. In addition, type II sIL-1R
does not interfere with inhibition of IL-1 signaling medi-
ated by the IL-1 receptor antagonist [10]. Since IL-1 is
involved in many inflammatory processes, the control of
IL-1 activity by the type II sIL-1R is important for the
understanding of these processes.
3. Soluble TNF-receptors
TNF-a is a potent proinflammatory cytokine, which is
released mainly by stimulated macrophages. It exerts its
biological activity through binding to two structurally
related but functionally independent cell surface receptors
(p55) and p75 [11,12]. Ligand binding leads to dimerisation
of receptor molecules and subsequent signal transduction.
Both receptors belong to the TNF-R gene family [13]. The
current state of view is that p55 is the primary signaling
receptor in most of the classical inflammatory responses
whereas the role of p75 is discussed controversially. It
seems to play a significant role in the stimulation of the
proliferation of T-cells. Moreover, it functions as a TNFa-
supplier or antagonist for the p55 receptors [14].
Both receptors are present as soluble forms in the
circulation and in other body fluids. They are generated
by shedding in consequence of a variety of inflammatory
Fig. 1. Generation of soluble receptors by shedding and differential splicing. Left: Activation of the shedding machinery leads to limited proteolysis of a
membrane expressed receptor protein. In the case of the human IL-6R, cleavage occurs between Gln357 and Asn358. Right: Alternative use of exons leads to the
generation of an mRNA lacking the exon coding for the transmembrane domain (red). Consequently, a soluble receptor is secreted by the cell. Due to the usage
of an alternative reading frame, this leads in the case of the human IL-6R to an additional amino acid sequence not found in the transmembrane version of the
receptor.
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stimuli. The biological function of these soluble forms is
assumed to be antagonistic by competition with the mem-
brane-bound receptors. On the other hand, the half-life of
TNFa in the circulation might be prolonged and the
interaction with membrane-bound receptors might be facili-
tated [15]. Therefore, the biological response to TNFa in a
physiological context is dependent on the number and type
of cell surface receptors and on the amount of soluble
receptors in the body compartment.
TNFa is thought to play a key role in many inflammatory
diseases including sepsis, rheumatoid arthritis and inflam-
matory bowel diseases, in particular Crohn disease (CD).
Although TNFa is not the causative agent of these diseases,
it has a major influence on its manifestation by perpetuating
the inflammatory response. This central role of TNFa led to
the development of various TNF-antagonists for clinical
purposes [16].
Besides chimeric or humanized anti-TNF-antibodies,
TNFa-antagonists on the structural basis of sTNF-Rs have
been developed. The use of such receptors is limited by their
short plasma half-life and high doses of soluble receptor
protein needed to neutralise TNFa due to relatively low
affinities. These drawbacks can at least partially be circum-
vented by using Fc fusion proteins or PEG-linked proteins.
At the present time the most effective TNF-antagonist
structurally related to sTNF-R is a soluble p75–Fc dimer
[15] sold under the name ‘Etanercept’. It was successfully
used in patients with rheumatoid arthritis and was approved
by the food and drug administration in 1998. As a ther-
apeutic, Etanercept has been shown to significantly decrease
the degree of pain and swelling in inflamed joints and serves
to down-regulate levels of C-reactive protein. Although
doses of Etanercept are generally well tolerated, individuals
receiving Etanercept are more susceptible to infection and
show an impaired ability to clear microbes [17]. These side
effects potentially arise from the antagonistic properties of
Etanercept which blocks the inflammatory response at its
inception. Other applications are currently under investiga-
tion including CD, psoriasis and heart failure.
4. The gp130 cytokine family and the paradigm of
transsignaling
Soluble receptors of the gp130 cytokine family have
been characterized in great detail with respect to their
generation and physiological function, and are the primary
focus of this review. The gp130 family is defined by the fact
that all its members use g130 as at least one of the subunits
of their cell surface receptor complexes. The IL-6 cytokine
family consists of IL-6, IL-11, LIF, oncostatin M (OSM),
cardiotrophin-1 (CT-1), ciliary neurotrophic factor (CNTF)
and novel neurotrophin-1/B cell-stimulating factor-3 (NNT-
1/BSF-3, also designated cardiotrophin-like cytokine (CLC)
[18, 19]. The set-up of the receptor complexes of gp130
cytokines is shown in Fig. 2A.
As shown in Fig. 2B, on target cells, IL-6 binds to a
specific IL-6 receptor (IL-6R) and this complex associates
with two molecules of the ubiquitously expressed gp130
leading to initiation of signaling [20].
Table 1
Soluble alpha-receptors and their function
Receptor Shedding
splicing
Reported
function
Referencea
IL-1RI shedding role of IL-1RA [118]
IL-1RII shedding role of IL-1RA [118]
IL-2R shedding antagonistic [119]
IL-3R – antagonistic [120]
IL-4R shedding
and splicing
antagonistic [121]
IL-5R splicing protein not detected [122]
IL-6R shedding
and splicing
sensitisation
and transsignaling
[7,33]
IL-7R splicing protein not detected [123]
IL-9R splicing protein not detected [124]
IL-10R – antagonistic [125]
IL-11R – sensitisation
and transsignaling
[126]
IL-12R
subunit
– antagonistic [127]
IL-13R – antagonistic [128]
IL-15R – antagonistic [129]
IL-18 Binding
Protein
splicing antagonist [130]
IL-22 secreted antagonist [131,132]
CNTF-R shedding
secreted
complexed
with CLC
agonistic when
complexed
with CLC
[44,45]
CT-1 – –
CLC-R
CLC/CLF
CLC/sCNTFR
soluble only chaperone function [19]
TNF-RI shedding inhibition [133]
TNF-RII shedding inhibition [133]
The a-chain generally refers to the subunit dictating ligand specificity. The
‘– ’ symbol is used to highlight where current information is lacking.
a Recent review articles.
Table 2
Soluble beta/gamma-receptors and their function
Receptor Shedding
splicing
Reported
function
Referencea
gp130 splicing inhibition of
transsignaling
[33]
LIF-Rh splicing soluble gp190
antagonist
[134]
OSM-Rh Potential
spliced
products
potential candidates
as Genbank entries
[135]
IL-2Rh splicing – [119]
IL-2Rg – – [119]
The h- and g-subunit transmit the intracellular signal as a result of cytokine
interaction with its specific a-chain. The ‘– ’ symbol is used to highlight
where current information is lacking.
a Recent review articles.
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The IL-6R protein has been shown to exist in membrane
bound and soluble form [21,22]. Although cells that do not
express IL-6R are nonresponsive to IL-6 alone, these cells
can be stimulated by a complex of IL-6 and sIL-6R [23,24].
Therefore, cells which release the sIL-6R protein render
cells which only express gp130 responsive towards the
cytokine IL-6 (Fig. 3). This pathway has recently been
termed ‘transsignaling’ [1,25]. Furthermore, IL-6-respon-
sive cells are sensitized by the presence of the sIL-6R
protein [26]. Cells that express gp130 but do not respond
to IL-6 alone include haematopoietic progenitor cells [27],
osteoclasts [28] and neuronal cells [29].
The sIL-6R is present in the plasma of healthy individ-
uals (f 25–35 ng/ml) and elevated levels of this soluble
receptor have been detected in numerous disease states.
Thus, sIL-6R has the potential to regulate both local and
systemic IL-6-mediated responses (see later sections). As a
result, it is necessary that the cellular events controlled by
IL-6 itself be distinguished from those elicited by the [sIL-
6R/IL-6] complex. Addressing this issue is, however, con-
founded by the observation that both differential IL-6R
mRNA splicing [30,31] and proteolytic (shedding) cleavage
of the cognate IL-6R [21,32] contribute to generation of a
sIL-6R (Fig. 1). Although both forms are structurally
related, the differentially spliced variant can be distin-
guished from the shed form by a novel proximal COOH-
terminal sequence (GSRRRGSCGL), which is introduced as
a consequence of the splicing process [30]. Thus, two
distinct sIL-6R isoforms control the overall properties of
this soluble receptor. These isoforms have been referred to
as DS-sIL-6R and PC-sIL-6R to denote release via differ-
ential mRNA splicing (DS) and proteolytic cleavage (PC)
[7]. To date, it is unclear why two mechanisms control sIL-
6R release. For a more detailed review of the sIL-6R
isoforms, the reader is directed elsewhere [7,33].
Previous studies have established that cellular release of
both isoforms is differentially regulated [34–36]. Indeed,
antibodies specifically raised against the unique COOH-
terminal sequence of DS-sIL-6R have demonstrated in vivo
and in vitro expression of this spliced variant, and have
shown that release of each isoform ultimately depends on
the individuals age, the inflammatory condition and stage of
disease progression [30,35,37,38]. Using such an approach,
we have recently assessed temporal changes in the release of
both forms during progression of acute inflammation [39].
Analysis of peritoneal effluent from end-stage renal failure
patients on continuous ambulatory peritoneal dialysis with
overt clinical peritonitis established that initial (day 1–2 of
infection) increases in sIL-6R levels are derived from
proteolytic shedding [39]. These increases in sIL-6R con-
centration were found to directly correlate (r = 0.88) with the
number of neutrophils that infiltrate the peritoneal cavity.
Indeed, human neutrophils have been shown not to release
Fig. 2. Receptors for the IL-6 family of cytokines. (A) Receptor complexes
are composed of the signaling subunits gp130 (burgundy), LIF-R (dark blue)
and OSM-R (lilac) and additional specific ligand binding receptors (black,
yellow, pink, green). IL-6 and IL-11 signal via a homodimer of gp130
whereas CNTF, CT-1 and NNT-1 use a heterodimer of gp130 and LIF-R.
Note that LIF and OSM do not use specific binding receptors. In the case of
human OSM, an alternative receptor complex consisting of gp130 and
OSM-R has been reported. (B) IL-6 (blue) first binds to the specific IL-6R
(black) forming the IL-6/IL-6R complex. This complex associates with
gp130 (red), induces gp130 dimerisation and signal initiation. Note that
neither IL-6 nor IL-6R on their own exhibits a measurable affinity for
gp130.
Fig. 3. Transsignaling of receptors for the IL-6 family of cytokines. The
sIL-6R (black) generated by shedding or alternative splicing binds its ligand
(blue) with comparable affinity as the membrane expressed IL-6R. The IL-
6/sIL-6R complex associates with expressed gp130 (red) expressed on a
cell with no IL-6R expression, induces dimerisation and initiates signaling.
Cells that only express gp130 but not IL-6R are unable to respond to IL-6.
Activation of such cells in the presence of sIL-6R is called transsignaling
since the sIL-6R generated by one cell type enables a second cell type to
respond to the cytokine.
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detectable levels of DS-sIL-6R, whereas stimulation of
neutrophils with C-reactive protein [40], f-MLP [41], and
neutrophil-activating chemokines [39,42] increases IL-6R
shedding. C-reactive protein has also been found to induce
IL-6R shedding from human monocytes/macrophages [43].
In contrast, DS-sIL-6R levels did not peak until day 3 of
infection and coincided with the onset of intraperitoneal
mononuclear leukocyte accumulation [39]. Currently, little
is known about the expression of DS-sIL-6R, however,
studies have shown that oncostatin-M [34] and viral infec-
tions [30,37] mediate release of this isoform. Thus, levels of
PC- and DS-sIL-6R are differentially regulated during
disease progression, which implies that each isoform might
function at distinct stages of an inflammatory process and
the importance of sIL-6R in regulating leukocyte recruit-
ment will be discussed in a later section of this review.
The properties of the sIL-6R/IL-6 complex as an agonist
is not unique to IL-6. The IL-11R, CNTF-R as well as the
CT-1 receptor have been found to act agonistically on target
cells, which only expressed the signaling receptors gp130
and LIF-R [44–46]. Recent studies have shown that another
IL-6 family member, CLC, which is also known as NNT-1/
BSF-3, also behaves in a similar fashion. However, unlike
the sIL-6R/IL-6 complex, CLC is secreted from cells as
either a complex with the soluble receptor cytokine-like
factor-1 (CLF), or in association with the soluble ciliary
neurotrophic factor receptor-a (sCNTFR) [19,47]. Expres-
sion of CLF is required for CLC secretion, and the CLC/
CLF complex activates cell types expressing the cognate
CNTF receptor; however, when bound with sCNTFR, the
CLC/sCNTFR heterocomplex displays functional activities
on cells expressing gp130 and the LIF receptor (LIFR or
gp190). In this respect, both CLC/CLF and CLC/sCNTFR
have been shown to have an important function in neuronal
cell activation [19,47].
5. sIL-6R and hematopoiesis
To elucidate the in vivo role of the IL-6/sIL-6R system,
double transgenic mice were constructed which expressed
both, human IL-6 and the sIL-6R [48]. One of the most
remarkable phenotypic alterations found in these mice was
an extramedullary hematopoiesis mainly in spleen and liver.
No such hematopoiesis was seen in IL-6 transgenic mice
and control animals. Since all lineages of the blood were
affected, it was hypothesized that the IL-6/sIL-6R stimula-
tion had resulted in an expansion of hematopoietic progen-
itor cells. These data seemed reminiscent to data reported by
the group of Nakahata that direct stimulation of gp130 on
hematopoietic progenitor cells by IL-6 and sIL-6R but not
by IL-6 alone resulted in efficient expansion of early
progenitors [27]. It had turned out that early hematopoietic
progenitor cells did not express cell surface IL-6R whereas
more differentiated hematopoietic cells were characterized
by IL-6R expression [49].
Treatment of human and murine hematopoietic progen-
itor cells with the IL-6/sIL-6R fusion protein Hyper-IL-6
(see below) in combination with the hematopoietic cyto-
kines stem cell factor and flt-3 ligand resulted in an efficient
expansion of hematopoietic progenitor cells with much less
concomitant cellular differentiation than with other cytokine
cocktails [50–55]. Expanded cell populations could even be
used to stimulate the differentiation of functional dendritic
cells [56–58], demonstrating the biotechnological potential
of massive gp130 stimulation by IL-6/sIL-6R.
6. sIL-6R and liver regeneration
Mice expressing both the human IL-6R and human IL-6
as transgenes showed extensive proliferation of hepatocytes
[59, 60]. No such effect was seen in IL-6 single transgenic
animals. These findings indicated a functional role of the IL-
6/sIL-6R system in the regulation of hepatocellular prolif-
eration, e.g. during liver regeneration. Subsequent studies
showed that application of the IL-6/sIL-6R fusion protein
Hyper-IL-6 (see below) drastically accelerated liver regen-
eration after partial hepatectomy [61]. Moreover, animals
survived chemically induced liver damage after injection of
the IL-6/sIL-6R fusion protein [62]. Moreover, application
of an adenovirus coding for the IL-6/sIL-6R fusion protein
resulted in survival of the animals [63]. These data demon-
strate the role of the gp130 system in governing hepatocyte
proliferation control. In addition, a potential therapeutic
application of gp130 stimulation in liver disorders seems
to be feasible.
7. sIL-6R in arthritis
Elevated sIL-6R levels have been observed in rheuma-
toid arthritis and juvenile rheumatoid arthritis and osteo-
arthritis [64–66]; however, the increase observed in
rheumatoid arthritis are considerably more pronounced than
those encountered in osteoarthritic patients [65]. Indeed,
sIL-6R and IL-6 levels appear to be highest in the more
progressive stages of rheumatoid arthritis [66]. The presence
of elevated sIL-6R concentrations in arthritis strongly sug-
gests that sIL-6R release is regulated as part of the inflam-
matory process. It is, however, difficult to judge whether the
elevated sIL-6R levels associated with this disease are
derived from systemic or local sources (Fig. 4) [67]. To
date, the cellular origin of sIL-6R in arthritis remains
unknown, although cell types resident to the joint (chon-
drocytes, synoviocytes, fibroblasts and endothelial cells)
seem unlikely to contribute to the sIL-6R levels encountered
[67]. It is therefore conceivable that sIL-6R may be released
from activated leukocytes, which have been shown to
release sIL-6R [39–41]. This may account for the observed
correlation between the infiltration of leukocytes into
arthritic joints and the increased concentration of sIL-6R
S.A. Jones, S. Rose-John / Biochimica et Biophysica Acta 1592 (2002) 251–263 255
in synovial fluid [67]. However, since systemically elevated
sIL-6R levels have been detected in systemic onset juvenile
chronic arthritis [64], it is also important that other sources
are considered.
A series of in vitro approaches have now pointed to a
role for sIL-6R in a variety of cellular events typically
associated with arthritic lesions, for instance, the severe
destruction of cartilage and bone. Indeed, levels of sIL-6R
and IL-6 in synovial fluid from arthritic patients have been
shown to correlate with the increased concentration of
these mediators and to promote formation of osteoclast-
like cells when added to cocultures of osteoblastic cells
and bone marrow cells [65]. A further role for sIL-6R in
bone matrix degradation and resorption is also emphasized
by the observation that rat osteoblasts release collagenase-3
following co-stimulation with IL-6 and sIL-6R [68]. In
addition to bone remodeling, the [sIL-6R/IL-6] complex
may partially account for the loss of proteoglycan com-
monly associated with arthritic lesions since its activity is
associated with suppression of proteoglycan synthesis [69].
Similarly, IL-6 and its soluble receptor have been reported
to augment aggrecanase-mediated catabolism of proteogly-
can in articular cartilage [70] (Fig. 4). Collectively, these
findings infer that sIL-6R actively contributes to the
processes involved in joint destruction; however, experi-
ments using human articular synovial fibroblasts and
chondrocytes have shown that sIL-6R may have protective
properties in arthritis and can block the collagenolytic
activity of conditioned medium from IL-1-induced syno-
viocytes [71].
8. sIL-6R and inflammatory bowl disease
It was shown that IL-6 has a significant contribution
to the increased resistance of mucosal T cells against
apoptosis in CD, a chronic inflammatory disease of the
gastrointestinal tract [43]. A neutralizing antibody against
IL-6R suppressed established experimental colitis in var-
ious animal models of CD mediated by type 1 T-helper
cells, by inducing apoptosis of lamina propria T cells.
Similarly, specific neutralisation of sIL-6R in vivo by a
gp130–Fc fusion protein [72,73] caused suppression of
colitis activity and induction of apoptosis, indicating that
sIL-6R prevents mucosal T-cell apoptosis. In patients
with CD, mucosal T cells showed strong evidence for
IL-6 transsignaling, with activation of signal transducer
and activator of transcription 3 (STAT-3), bcl-2 and
bclXL. Specific blockade of IL-6 transsignaling by soluble
gp130 (see below) caused T-cell apoptosis, indicating that
the IL-6–sIL-6R system mediates the resistance of T cells
to apoptosis in CD. These data indicate that a pathway of
T-cell activation driven by IL-6–sIL-6R contributes to the
perpetuation of chronic intestinal inflammation. Specific
targeting of this pathway with a gp130–Fc fusion protein
may be a promising new approach for the treatment of
CD [43,73].
9. The regulation of leukocyte recruitment by the sIL-6R
Although the role of sIL-6R during inflammation
remains largely unclear, recent studies have shown that
sIL-6R-mediated events may control leukocyte infiltration
[39,41,74–76]. Through examination of IL-6-deficient IL-
6 / mice, it was initially inferred that IL-6 could sup-
press the accumulation of neutrophils at sites of infection
or inflammation [77,78]. In vitro studies subsequently
demonstrated that activation of various cell types by the
sIL-6R/IL-6 complex could promote chemokine (CXCL8/
IL-8, CCL2/MCP-1 and CCL8/MCP-3) and adhesion mol-
ecule (ICAM-1, VCAM-1) expression [39,41,74–76] (Fig.
Fig. 4. The sIL-6R/IL-6 complex in arthritis: evidence of in vivo and in vitro consequences.
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5). The potential importance of these findings is clearly
indicated by clinical studies that have reported a correla-
tion between the degree of leukocyte recruitment encoun-
tered during an inflammatory insult and locally elevated
levels of sIL-6R [7,39]. Consequently, sIL-6R-mediated
signaling appears to have an impact on the regulation of
leukocyte infiltration. However, the functional importance
of this activity was not fully appreciated until a recent
study examined the role of sIL-6R in acute inflammatory
episodes of bacterial peritonitis. Leukocyte recruitment
during acute inflammation is characterized by an initial
infiltration of neutrophils, which are later replaced by a
more sustained influx of mononuclear cells [79], and
studies showed that IL-6 and its soluble receptor have a
controlling influence on this pattern of infiltration [39]. In
particular, liberation of sIL-6R from the initial neutrophil
infiltrate was found to differentially regulate CXC- and
CC-chemokine expression to suppress neutrophil recruit-
ment, whilst concurrently promoting attraction of mono-
nuclear leukocytes [39]. sIL-6R-mediated signaling is
therefore an important intermediary event in the resolution
of inflammation and supports transition between the early,
predominantly neutrophilic stage of an infection, and the
more sustained mononuclear cell influx, thus, suggesting
that sIL-6R transsignaling could differentially regulate the
phenotype of leukocytes recruited to sites of acute inflam-
mation [39]. It remains to be determined whether regula-
tion of leukocyte recruitment by sIL-6R has an impact on
the progression of conditions such as arthritis, where IL-6
has been shown to have a prominent role in several in vivo
studies [80–83]. An overview of the role of sIL-6R in the
regulation of leukocyte recruitment is given in Fig. 5.
10. sIL-6R and neural cells
It was shown that many neural cells including primary
rat sympathetic neurons [84], human fetal astrocytes [85],
primary sensory neurons from dorsal root ganglia [86],
newborn rat brain astrocytes [87] and rat pheochromocy-
toma cells (PC12) [88] only react to IL-6 in the presence
of sIL-6R. The effects observed range from induction of
expression of the neuropeptides choline acetyltransferase,
substance P, cholecystokinin and neuronal survival [84],
Fig. 5. Leukocyte attraction by chemokine responses elicited by inflammatory cytokines during peritonitis. Peritonitis is characterized by a rapid initial
accumulation of neutrophils (PMN) followed by a rise of mononuclear cells (insert). (1) Infection leads to the release of the inflammatory cytokines IL-1h,
TNFa and IL-6. Peritoneal mesothelial cells are not responsive to IL-6 but are responsive to IL-1h and TNFa. This leads to a release of CXC chemokines and
subsequently to the attraction of neutrophils. (2) Neutrophils shed their membrane-expressed IL-6R due to the presence of CRP, fMLP and CXC chemokines.
The sIL-6R combines with the IL-6 and leads to a response of the peritoneal mesothelial cells. Now the expression of CXC chemokines is suppressed whereas
secretion of CC chemokines is triggered. (3) This leads to a replacement of neutrophils by mononuclear cells. Therefore, the sequence of neutrophils to
mononuclear cells seems to be governed by the appearance of sIL-6R which is shed from neutrophils.
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to inhibition by Hyper-IL-6 of the VCAM-1 upregulation
induced by TNFa [85] and induction of astrocyte differ-
entiation and region-specific neurotrophin (NT3; NT4,5)
induction [88]. It was concluded that transsignaling is an
important event in neuronal differentiation and survival
responses [29] (Fig. 6).
11. The construction of the designer cytokine hyper-IL-6
The effective concentration of IL-6 (50 ng/ml) and sIL-6R
(1000 ng/ml) [27] needed for the stimulation of human
hematopoietic progenitor cells is high, considering a Kd of
approximately 1 nmol/l [89,90]. Recently, it has been
reported that the ligand/receptor interaction is mainly deter-
mined by the off-rate [91], suggesting that the average half-
life of the IL-6/sIL-6R complexmight be shorter than the time
needed to assemble the IL-6/sIL-6R/gp130 complex. Accord-
ingly, to lower the effective dose needed for IL-6 bioactivity,
IL-6 muteins with a lower off-rate have been generated that
render the complexes with IL-6Rmore stable [92]. As a novel
approach, we postulated that the formation of the IL-6/IL-6R
complex could be enhanced by converting it into an unim-
olecular protein by using a polypeptide as a linker. The
distance between the C terminus of IL-6R and the N terminus
of IL-6 was calculated from our three-dimensional model of
the complex to be in the order of 40 A˚ [93,94]. Consequently,
we used the 16 NH2-terminal nonhelical and presumably
flexible amino acid residues of human IL-6 together with a
13-residue sequence rich in glycine and serine to connect IL-
6 and the sIL-6R [95]. On gp130-expressing cells, the fusion
protein that we call Hyper-IL-6 turned out to be fully active at
100- to 1000-lower concentrations compared with the com-
bination unlinked IL-6 and IL-6R [96]. The fusion protein
was therefore tested for its ability to stimulate expansion of
hematopoietic progenitor cells in vitro. It turned out that
Fig. 6. Neural cells require sIL-6R to be responsive to IL-6. Left panel: Rat primary cultures of cortical astrocytes were stimulated for 7 days by medium alone
(control, C), 10 ng/ml human IL-6 or 10 ng/ml IL-6/sIL-6R fusion protein (H-IL-6). Astrocytes were stained for glial fibrillary acidic protein (GFAP). Middle
panel: Rat pheochromocytoma cells (PC12) were analyzed for neurite outgrowth/differentiation after 3 days of stimulation with medium alone (control, C), 10
ng/ml human IL-6 or 10 ng/ml IL-6/sIL-6R fusion protein (H-IL-6). Right panel: Rat primary sympathetic neurons were cultured in the presence of cytosine
arabinoside with medium alone (control, C), 10 ng/ml human IL-6 or 10 ng/ml IL-6/sIL-6R fusion protein (H-IL-6), and analyzed for neuronal survival and
differentiation. Neurons grown in medium without supplements or supplemented with IL-6 alone did not survive and could not be further analyzed.
Sympathetic neurons in the presence of the IL-6/sIL-6R fusion protein H-IL-6 survived and showed characteristic differentiation. After 6 days in culture,
neurons were stained for tyrosine hydroxylase (TH) immunoreactivity. Experiments were monitored by phase-contrast microscopy, magnification  100 [29].
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stimulation with Hyper-IL-6 was at least as effective as IL-6/
sIL-6R at 100 lower concentrations than those used for
unlinked IL-6-IL-6R [95,96].
Therefore, the Hyper-IL-6 recombinant protein like the
IL-6 and sIL-6R double transgenic mice [48,59,60] has
proven to be an invaluable tool to characterize potential
target cells of transsignaling. Moreover, this protein might
have some potential for the treatment of acute liver failure
[61–63] and for the ex vivo expansion of hematopoietic
progenitor cells [50].
12. Viral IL-6
The genome of human herpesvirus 8 (HHV8), which is
associated with Kaposi sarcoma and Castleman Disease
[97], encodes proteins with similarities to cytokines and
chemokines including a homologue of IL-6 named viral IL-
6 (vIL-6) [98,99]. For vIL-6 it has been demonstrated that it
stimulates IL-6-dependent cells, indicating that the IL-6
receptor system is used. We showed that purified recombi-
nant vIL-6 binds directly to gp130, and stimulates primary
human smooth muscle cells. IL-6R fails to bind vIL-6 and is
not involved in its signaling. An Fc fusion protein of gp130
[72,73] turned out to be a potent inhibitor of vIL-6. Our data
demonstrate that vIL-6 is the first cytokine which directly
binds to and activates gp130 [100,101]. The direct inter-
action of vIL-6 with gp130 without a necessary interaction
of the IL-6R was directly demonstrated by the solution of
the 3D structure of vIL-6 in complex with the extracellular
portion of gp130. It turned out that two molecules of vIL-6
are complexed in a ring-like fashion with two molecules of
gp130 [102]. The property of direct gp130 activation allows
vIL-6 to stimulate virtually all cells in the body, whereas
stimulation by human IL-6 in the absence of sIL-6R is
restricted to cells that express IL-6R on the membrane. This
notion points to a possible role of this viral cytokine in the
pathophysiology of HHV8-related diseases.
13. Antagonism of sIL-6R-mediated signaling
To ensure that the agonistic properties of the sIL-6R are
tightly regulated, the activity of the sIL-6R/IL-6 complex is
counteracted by the presence of a soluble form of gp130
[73,103,104]. Relatively high circulating levels of sgp130
(f100–300 ng/ml) are detected in human sera and sgp130
associates with the sIL-6R/IL-6 complex to inhibit signal-
ing via membrane-bound gp130 [104–106]. Soluble gp130
has been shown to inhibit sIL-6R-mediated proliferation of
Kaposi sarcoma cells [107], STAT activation and the
expression of a1-antichymotrypsin [73,103]. It has been
concluded that sgp130 is the natural inhibitor of IL-6/sIL-
6R responses [73] which without such an inhibitor could
lead to the stimulation of virtually all cells in the body
(Fig. 7).
Indeed, we have shown that sgp130 can modulate
leukocyte recruitment in a murine model of acute inflam-
mation [39] and suppress the clinical indices of exper-
imental colitis [43]. Recently, it was hypothesized that sIL-
6R acts as an antagonistic molecule that enhances the
inhibitory capacity of sgp130 [103]. This conclusion was
based on the observation that although sgp130 could not
block IL-6-induced activation of IL-6R expressing cells,
inclusion of sIL-6R in the assay set-up enhanced the
antagonistic properties of sgp130 by promoting formation
of an IL-6–sIL-6R–sgp130 tertiary complex. Hence,
sgp130 and sIL-6R together may prevent IL-6 signaling
through its cognate receptor. Interestingly, the inhibitory
action of sgp130 is not restricted to suppressing sIL-6R
signaling and has been found to block LIF- and OSM-
mediated events although to a much lesser extent [73,108].
This may in part account for the high levels of sgp130
detected in the plasma of healthy and diseased individuals.
However, in vitro studies have suggested that sgp130 has a
lower affinity for LIF and OSM than for the sIL-6R/IL-6
complex [73], suggesting that other more specific factors
may control the action of other gp130-activating cytokines.
Thus, when considering the impact of the gp130-related
cytokines during disease progression, it is necessary to
consider the time frame of their induction with that of
sgp130 production. In this respect, examination of a recently
developed SCID mouse model for multiple myeloma
revealed that increases in sIL-6R levels precede those of
sgp130 [109]. This emphasizes the necessity to understand
how sgp130 levels regulated in vivo.
Fig. 7. Soluble gp130 is the natural inhibitor of IL-6/sIL-6R responses.
(A) IL-6 (blue) cannot bind to the sgp130 protein (red). In contrast, IL-6
binds to the membrane expressed IL-6R. Soluble gp130 has no access to IL-
6 complexed by IL-6R and two molecules of membrane-bound gp130 and
therefore exhibits no inhibitory activity. (B) The IL-6/sIL-6R complex (blue,
black) can equally bind to both membrane-bound and sgp130 proteins (red).
Consequently, a molar excess of sgp130 leads to competitive inhibition of
the IL-6/sIL-6R response [73].
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Soluble cytokine receptors are typically generated
through either proteolytic shedding cleavage (PC) or as
the product of differential mRNA splicing (DS). Several
studies have examined the mechanisms controlling sgp130
production and, as with sIL-6R release, both mechanisms
have been implicated in regulating its liberation [7,110].
Indeed, both 50–90- and 110-kDa forms of gp130 have
been identified in serum [104,108,111,112]. Examination
of gp130 shedding in a cell line transfected with cDNA
encoding for the membrane-bound gp130 has shown that
phorbol esters induce shedding of this protein, however,
the degree of release was considerably less than that
observed for the IL-6 receptor [110]. In contrast, PCR
approaches have identified a spliced variant of gp130
containing an additional 85-base pair insertion. This
DNA insertion results in translation of a novel COOH-
terminal sequence consisting of 27 novel residues
(WIHYGFFTWLESCQRGPYSLVEEILHN) and terminat-
ing with a stop codon prior to the transmembrane encoding
region of the gp130 mRNA [108].
Recently, a third isoform of sgp130 was identified as
an autoantigen in rheumatoid arthritis [111]. This 50-kDa
protein is termed gp130-RAPS (gp130 of the Rheumatoid
arthritis Antigenic Peptide-bearing Soluble form) and is
translated from an alternatively spliced mRNA and pos-
sesses a unique COOH-terminal sequence (NIASF) [111].
High incidence of serum antibodies against this NIASF
sequence have been detected in RA patients and these
levels correlate with disease activity indices such as
serum C-reactive protein levels [111]. A fourth sgp130
variant has also been identified, however, its expression
is confined to embryonic cells [113]. Thus, the overall
properties of sgp130 in vivo are coordinated by at least
four independent sgp130 isoforms.
14. sIL-6R and the cellular decision of differentiation
The cellular differentiation of murine embryonic stem
cells is completely blocked by the treatment of such cells
with the gp130 cytokine LIF. This is the basis to in vitro
manipulate murine embryonic stem cells to generate
gene-targeted mice (knock-out mice) [114]. Treatment of
these cells by LIF can be replaced by stimulation of the
cells with IL-6/sIL-6R [115,116]. Since LIF requires the
presence of gp130 and LIF-R on the cell surface of stem
cells but IL-6/sIL-6R only requires the presence of the
ubiquitously expressed receptor gp130, stimulation of
stem cells by IL-6/sIL-6R might be more universal than
stimulation of the cells by LIF. Furthermore, it has been
demonstrated that activation of STAT3 is necessary and
sufficient for the maintenance of the undifferentiated state
of stem cells [117] (Fig. 8). Gp130 is the most potent
activator of STAT3 and the designer cytokine Hyper-IL-6
is the most potent activator of gp130. Therefore, it
appears that Hyper-IL-6 has a promising potential for
the maintenance of the undifferentiated state of stem cells
(Fig. 8).
Fig. 8. Block of differentiation by gp130 signaling. Left: Murine embryonic stem cells (pink) treated with the gp130 cytokine LIF exhibit a block in
differentiation. This is due to stimulation of membrane-bound gp130 (red) and LIF-R (blue). This phenomenon can be exploited to genetically manipulate these
cells in culture. Right: Hematopoietic stem cells treated with IL-6/sIL-6R show a similar block of differentiation due to stimulation of membrane expressed
gp130 (red) and can be expanded with the addition of the hematopoietic cytokines SCF and Flt-3L. Therefore, the IL-6/sIL-6R fusion protein H-IL-6 might be a
good candidate to block differentiation of embryonic stem cells of other species including man.
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15. Concluding remarks
Soluble cytokine receptors are important regulators of the
cytokine network and contribute not only to the control of
cytokine activities during disease, but also during normal
homeostasis. In this respect, this review has primarily
concentrated on the role performed by the sIL-6R, which
forms a ligand–receptor complex with IL-6 to stimulate
proliferation, differentiation and inflammatory processes.
Through a series of in vitro investigations it is now apparent
that sIL-6R contributes to the activation of a wide variety of
cellular processes, however, researchers are only now
beginning to understand the functional importance of this
receptor in vivo. These studies have clearly identified a set
of questions which need to be considered if we are to fully
appreciate the physiological impact sIL-6R, as well as all
other soluble cytokine receptors. In this respect, it is
essential for us to identify how a receptor is regulated, to
ask when is it likely to be produced and whether it will elicit
a global (systemic) or localized effect. Ultimately, these
considerations are directly pertinent to investigations into
other biological mediators, but their significance is clearly
emphasized by recent studies into the inflammatory proper-
ties of sIL-6R [39,43].
These findings also emphasize another key issue in the
regulation of cytokine responses by soluble receptors.
Clearly, cytokines are able to bind to either their cognate
membrane-bound receptors or to their soluble counterparts.
Consequently, the action of any given cytokine will ulti-
mately depend on the relative abundance of each form. In
terms of soluble receptors that act as antagonists, this will
invariably determine whether a cytokine is active or not. In
the case of the agonistic soluble cytokine receptors, the
situation may be even more complex. sIL-6R was recently
proposed to act as an antagonistic molecule that facilitates
the inhibitory capacity of sgp130 [103]. This was based on
the observation that although sgp130 could not block IL-6-
induced activation of IL-6R expressing cells, addition of
sIL-6R could enhance the antagonistic properties of sgp130
by promoting formation of an IL-6–sIL-6R–sgp130 tertiary
complex. Hence, sgp130 and sIL-6R may also act together
to prevent IL-6 signaling through the cognate receptor.
Invariably this again emphasizes the need to consider the
temporal expression of each of the membrane expressed and
soluble receptor components.
In terms of regulating local inflammatory responses, it is
apparent that the generation of IL-6 by cell types resident to
a site of immunological challenge serves a largely redundant
role since expression of the cognate IL-6R is confined to
hepatocytes and leukocytes. sIL-6R generation is therefore a
rate-limiting event. During acute inflammation, for instance,
this is overcome by the infiltration of leukocytes, which are
activated to release sIL-6R [39,40]. This infers that IL-6-
mediated events are not necessarily elicited when IL-6 is
generated, and in this respect optimal levels of IL-6 and sIL-
6R are detected at different stages during progression of the
inflammatory response [39]. The relevance of this temporal
production is emphasized by understanding the function of
sIL-6R during experimental episodes of inflammation. In
this respect, sIL-6R appears to be important in the resolution
of inflammation and is important in initiating recruitment of
leukocytes primarily involved in acquired immunity [39].
This may have a considerable bearing on chronic inflam-
matory conditions, since a breakdown in the regulation of
sIL-6R transsignaling appears to prevent the clearance of T-
lymphocytes and contributes to the development of exper-
imental colitis episodes [39,43]. Therefore, at least in the
case of IL-6, soluble receptors are critically involved in the
transition between the acute and sustained state of inflam-
matory situations and in the perpetuation of chronic inflam-
matory diseases [39,43].
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